Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?:

Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?: 1061988 TAM0010.1177/17588359211061988Therapeutic Advances in Medical OncologyA Donia, R Shahid et al. research-article20212021 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Can we develop oncolytic SARS-CoV-2 to 2021, Vol. 13: 1 –2 h DOI: 10.1177/ ttps://doi.org/10.1177 /17588359211061988 https://doi.org/10.1177/17588359211061988 specifically target cancer cells? © The Author(s), 2021. Article reuse guidelines: sagepub.com/journals- Ahmed Donia , Ramla Shahid, Muhammad Nawaz, Tahir Yaqub and permissions Habib Bokhari Correspondence to: Dear Editor inflammatory cytokines secreted in response to Ahmed Donia infection. Sollini and colleagues recently reported Department of Biosciences, Faculty We read with great interest the article by Ottaiano that a 61-year-old patient had complete remission of Science, COMSATS et al. titled “Unexpected tumor reduction in metastatic of follicular lymphoma after SARS-CoV-2 infec- University Islamabad, Islamabad 45550, Pakistan colorectal cancer patients during SARS-Cov-2 infec- tion, with exclusion of malignancy guided by ahmeddonia123@yahoo. tion” reporting a very interesting three colorectal computed tomography (CT) biopsy performed com cancer (mCRC) cases experiencing infection by twice. Habib Bokhari Department of severe acute respiratory syndrome coronavirus 2 Biosciences, Faculty (SARS-Cov-2), and all three patients surprisingly Keeping in mind the current cases of cancer of Science, COMSATS University Islamabad, showed improvement in mCRC disease burden. remission seen http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Therapeutic Advances in Medical Oncology SAGE

Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?:

Can we develop oncolytic SARS-CoV-2 to specifically target cancer cells?:

Therapeutic Advances in Medical Oncology , Volume 13: 1 – Dec 2, 2021

Abstract

1061988 TAM0010.1177/17588359211061988Therapeutic Advances in Medical OncologyA Donia, R Shahid et al. research-article20212021 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Can we develop oncolytic SARS-CoV-2 to 2021, Vol. 13: 1 –2 h DOI: 10.1177/ ttps://doi.org/10.1177 /17588359211061988 https://doi.org/10.1177/17588359211061988 specifically target cancer cells? © The Author(s), 2021. Article reuse guidelines: sagepub.com/journals- Ahmed Donia , Ramla Shahid, Muhammad Nawaz, Tahir Yaqub and permissions Habib Bokhari Correspondence to: Dear Editor inflammatory cytokines secreted in response to Ahmed Donia infection. Sollini and colleagues recently reported Department of Biosciences, Faculty We read with great interest the article by Ottaiano that a 61-year-old patient had complete remission of Science, COMSATS et al. titled “Unexpected tumor reduction in metastatic of follicular lymphoma after SARS-CoV-2 infec- University Islamabad, Islamabad 45550, Pakistan colorectal cancer patients during SARS-Cov-2 infec- tion, with exclusion of malignancy guided by ahmeddonia123@yahoo. tion” reporting a very interesting three colorectal computed tomography (CT) biopsy performed com cancer (mCRC) cases experiencing infection by twice. Habib Bokhari Department of severe acute respiratory syndrome coronavirus 2 Biosciences, Faculty (SARS-Cov-2), and all three patients surprisingly Keeping in mind the current cases of cancer of Science, COMSATS University Islamabad, showed improvement in mCRC disease burden. remission seen

Loading next page...
 
/lp/sage/can-we-develop-oncolytic-sars-cov-2-to-specifically-target-cancer-4j4JVCgCIh

References (13)

Publisher
SAGE
Copyright
Copyright © 2022 by SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses
ISSN
1758-8340
eISSN
1758-8359
DOI
10.1177/17588359211061988
Publisher site
See Article on Publisher Site

Abstract

1061988 TAM0010.1177/17588359211061988Therapeutic Advances in Medical OncologyA Donia, R Shahid et al. research-article20212021 Therapeutic Advances in Medical Oncology Letter to the Editor Ther Adv Med Oncol Can we develop oncolytic SARS-CoV-2 to 2021, Vol. 13: 1 –2 h DOI: 10.1177/ ttps://doi.org/10.1177 /17588359211061988 https://doi.org/10.1177/17588359211061988 specifically target cancer cells? © The Author(s), 2021. Article reuse guidelines: sagepub.com/journals- Ahmed Donia , Ramla Shahid, Muhammad Nawaz, Tahir Yaqub and permissions Habib Bokhari Correspondence to: Dear Editor inflammatory cytokines secreted in response to Ahmed Donia infection. Sollini and colleagues recently reported Department of Biosciences, Faculty We read with great interest the article by Ottaiano that a 61-year-old patient had complete remission of Science, COMSATS et al. titled “Unexpected tumor reduction in metastatic of follicular lymphoma after SARS-CoV-2 infec- University Islamabad, Islamabad 45550, Pakistan colorectal cancer patients during SARS-Cov-2 infec- tion, with exclusion of malignancy guided by ahmeddonia123@yahoo. tion” reporting a very interesting three colorectal computed tomography (CT) biopsy performed com cancer (mCRC) cases experiencing infection by twice. Habib Bokhari Department of severe acute respiratory syndrome coronavirus 2 Biosciences, Faculty (SARS-Cov-2), and all three patients surprisingly Keeping in mind the current cases of cancer of Science, COMSATS University Islamabad, showed improvement in mCRC disease burden. remission seen

Journal

Therapeutic Advances in Medical OncologySAGE

Published: Dec 2, 2021

There are no references for this article.